These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1312 related articles for article (PubMed ID: 18158288)

  • 1. Tumor suppressor LATS1 is a negative regulator of oncogene YAP.
    Hao Y; Chun A; Cheung K; Rashidi B; Yang X
    J Biol Chem; 2008 Feb; 283(9):5496-509. PubMed ID: 18158288
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angiomotins stimulate LATS kinase autophosphorylation and act as scaffolds that promote Hippo signaling.
    Mana-Capelli S; McCollum D
    J Biol Chem; 2018 Nov; 293(47):18230-18241. PubMed ID: 30266805
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mst2 and Lats kinases regulate apoptotic function of Yes kinase-associated protein (YAP).
    Oka T; Mazack V; Sudol M
    J Biol Chem; 2008 Oct; 283(41):27534-27546. PubMed ID: 18640976
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RAC-LATS1/2 signaling regulates YAP activity by switching between the YAP-binding partners TEAD4 and RUNX3.
    Jang JW; Kim MK; Lee YS; Lee JW; Kim DM; Song SH; Lee JY; Choi BY; Min B; Chi XZ; Bae SC
    Oncogene; 2017 Feb; 36(7):999-1011. PubMed ID: 27425596
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mammalian NDR/LATS protein kinases in hippo tumor suppressor signaling.
    Hergovich A; Hemmings BA
    Biofactors; 2009; 35(4):338-45. PubMed ID: 19484742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. WWC1 and NF2 Prevent the Development of Intrahepatic Cholangiocarcinoma by Regulating YAP/TAZ Activity through LATS in Mice.
    Park J; Kim JS; Nahm JH; Kim SK; Lee DH; Lim DS
    Mol Cells; 2020 May; 43(5):491-499. PubMed ID: 32451369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deubiquitinating Enzyme USP9X Suppresses Tumor Growth via LATS Kinase and Core Components of the Hippo Pathway.
    Toloczko A; Guo F; Yuen HF; Wen Q; Wood SA; Ong YS; Chan PY; Shaik AA; Gunaratne J; Dunne MJ; Hong W; Chan SW
    Cancer Res; 2017 Sep; 77(18):4921-4933. PubMed ID: 28720576
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Furry protein suppresses nuclear localization of yes-associated protein (YAP) by activating NDR kinase and binding to YAP.
    Irie K; Nagai T; Mizuno K
    J Biol Chem; 2020 Mar; 295(10):3017-3028. PubMed ID: 31996378
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum deprivation inhibits the transcriptional co-activator YAP and cell growth via phosphorylation of the 130-kDa isoform of Angiomotin by the LATS1/2 protein kinases.
    Adler JJ; Johnson DE; Heller BL; Bringman LR; Ranahan WP; Conwell MD; Sun Y; Hudmon A; Wells CD
    Proc Natl Acad Sci U S A; 2013 Oct; 110(43):17368-73. PubMed ID: 24101513
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MAP4K family kinases act in parallel to MST1/2 to activate LATS1/2 in the Hippo pathway.
    Meng Z; Moroishi T; Mottier-Pavie V; Plouffe SW; Hansen CG; Hong AW; Park HW; Mo JS; Lu W; Lu S; Flores F; Yu FX; Halder G; Guan KL
    Nat Commun; 2015 Oct; 6():8357. PubMed ID: 26437443
    [TBL] [Abstract][Full Text] [Related]  

  • 11. cAMP/PKA signalling reinforces the LATS-YAP pathway to fully suppress YAP in response to actin cytoskeletal changes.
    Kim M; Kim M; Lee S; Kuninaka S; Saya H; Lee H; Lee S; Lim DS
    EMBO J; 2013 May; 32(11):1543-55. PubMed ID: 23644383
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolic control of YAP and TAZ by the mevalonate pathway.
    Sorrentino G; Ruggeri N; Specchia V; Cordenonsi M; Mano M; Dupont S; Manfrin A; Ingallina E; Sommaggio R; Piazza S; Rosato A; Piccolo S; Del Sal G
    Nat Cell Biol; 2014 Apr; 16(4):357-66. PubMed ID: 24658687
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An evolutionarily conserved negative feedback mechanism in the Hippo pathway reflects functional difference between LATS1 and LATS2.
    Park GS; Oh H; Kim M; Kim T; Johnson RL; Irvine KD; Lim DS
    Oncotarget; 2016 Apr; 7(17):24063-75. PubMed ID: 27006470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intestinal regeneration: YAP-tumor suppressor and oncoprotein?
    Li VS; Clevers H
    Curr Biol; 2013 Feb; 23(3):R110-2. PubMed ID: 23391384
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Hippo pathway member Nf2 is required for inner cell mass specification.
    Cockburn K; Biechele S; Garner J; Rossant J
    Curr Biol; 2013 Jul; 23(13):1195-201. PubMed ID: 23791728
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The NDR/LATS protein kinases in immunology and cancer biology.
    Sharif AAD; Hergovich A
    Semin Cancer Biol; 2018 Feb; 48():104-114. PubMed ID: 28579171
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cellular energy stress induces AMPK-mediated regulation of YAP and the Hippo pathway.
    Mo JS; Meng Z; Kim YC; Park HW; Hansen CG; Kim S; Lim DS; Guan KL
    Nat Cell Biol; 2015 Apr; 17(4):500-10. PubMed ID: 25751140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of Angiomotin-like 2 mono-ubiquitination on YAP inhibition.
    Kim M; Kim M; Park SJ; Lee C; Lim DS
    EMBO Rep; 2016 Jan; 17(1):64-78. PubMed ID: 26598551
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elucidation of a universal size-control mechanism in Drosophila and mammals.
    Dong J; Feldmann G; Huang J; Wu S; Zhang N; Comerford SA; Gayyed MF; Anders RA; Maitra A; Pan D
    Cell; 2007 Sep; 130(6):1120-33. PubMed ID: 17889654
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Negative regulation of YAP by LATS1 underscores evolutionary conservation of the Drosophila Hippo pathway.
    Zhang J; Smolen GA; Haber DA
    Cancer Res; 2008 Apr; 68(8):2789-94. PubMed ID: 18413746
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 66.